AbbVie Q3 2026 Earnings - Q3 Adj EPS: $3.82 (est $3.74) - Humira Rev: $683M (est $679.3M) - Skyrizi Rev: $5.78B (est $5.74B) - Net Rev: $17.40B (est $17.34B) - Imbruvica Rev: $522M (est $527.3M) - Rinvoq Rev: $2.71B (est $2.7B) - Sees FY Adj EPS: $13.95 To $13.99 (prev guidance $13.76 To $13.96)

ABBVIE $ABBV Q3’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $17.40B (Est. $17.31B) 🟢; +10.3% YoY 🔹 Adj. EPS: $3.82 (Est. $3.75) 🟢; +100%+ YoY 🔹 Immunology Revenue: $9.17B; +16.3% YoY Raises FY26 Guide: 🔹 Adj. EPS: $13.95-$13.99 (Est. $13.92) 🟢; from $13.76-$13.96 Segment Net Revenue: 🔹 Immunology: $9.17B; +16.3% YoY 🔹 Neuroscience: $3.39B (Est. $3.29B) 🟢; +19.4% YoY 🔹 Oncology: $1.70B (Est. $1.68B) 🟢; +0.8% YoY 🔹 Aesthetics: $1.18B (Est. $1.20B) 🔴; -1.4% YoY Key Products: 🔹 Skyrizi: $5.78B (Est. $5.72B) 🟢; +22.7% YoY 🔹 Rinvoq: $2.71B (Est. $2.73B) 🔴; +23.9% YoY 🔹 Humira: $683M (Est. $695M) 🔴; -31.2% YoY 🔹 Venclexta: $803M (Est. $793M) 🟢; +10.7% YoY 🔹 Imbruvica: $522M (Est. $530M) 🔴; -26.1% YoY 🔹 Vraylar: $1.07B; +14.3% YoY Key Updates: 🔹 Apogee Therapeutics acquisition completed, deepening AbbVie’s immunology pipeline 🔹 IPR&D and milestones expense: $0.11/share unfavorable impact 🔹 Quarterly dividend raised to $1.82/share, payable February 16, 2027 Comments: 🔸 “Given our strong outlook and significant momentum, we are once again increasing AbbVie's full-year guidance and raising our quarterly dividend.”

AbbVie’s JUVMO (tavapadon) targets dopamine differently from older drugs and is expected in US pharmacies this month, the company says. #longevity# #AbbVie# #JUVMO# #tavapadon# #dopamine#

ABBVIE SAYS ITS FULL-YEAR 2026 ADJUSTED DILUTED EPS GUIDANCE RANGE INCLUDING BOUGHT IPR&D IS $13.76-$13.96 — BELOW THE $14.02 IBES VIEW — WITH Q3 2026 ADJUSTED DILUTED EPS GUIDANCE OF $3.73-$3.77 VERSUS A $3.84 VIEW.